We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s OPDP Raps Kaleo Social Media Post for Failure to Include Risk Information
FDA’s OPDP Raps Kaleo Social Media Post for Failure to Include Risk Information
Kaleo received an “untitled letter” from the FDA Office of Prescription Drug Promotion (OPDP) because one of the company’s social media posts for Auvi-Q (epinephrine injection) does not include any risk information about the drug.
